Comparison of the activity of two broad-spectrum cephalosporins tested against 2,299 strains of Pseudomonas aeruginosa isolated at 38 North American medical centers participating in the SENTRY antimicrobial surveillance program, 1997-1998

Diagnostic Microbiology and Infectious Disease

Volumn 36, Issue 2, 2000, Pages 125-129

  Ramphal, Reuben ^a   Hoban, Daryl J ^b   Pfaller, Michael A ^c   Jones, Ronald N ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; CEFAZOLIN; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; FURALTADONE; GATIFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; OFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TETRACYCLINE; TICARCILLIN; TIMENTIN; TOBRAMYCIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STANDARD; TECHNIQUE; UNITED STATES;

CEFTAZIDIME; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; CROSS INFECTION; DATABASES, FACTUAL; HUMANS; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; PSEUDOMONAS AERUGINOSA;

EID: 0033983928     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(99)00118-2     Document Type: Article

References (16)

1. Biedenbach D.J., Marshall S.A., Jones R.N. Accuracy of cefepime antimicrobial susceptibility testing results for Pseudomonas aeruginosa tested on the MicroScan WalkAway System. Diagn Microbiol Infect Dis. 33:1999;305-307.
2. Burwen D.R., Banerjee S.N., Gaynes R.P. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J Infect Dis. 170:1994;1622-1625.
3. Carmeli Y., Troillet N., Eliopoulos G.M., Samore M.H. Emergence of antibiotic-resistant Pseudomonas aeruginosa comparison of risks associated with different antipseudomonal agents . Antimicrob Agents Chemother. 43:1999;1379-1382.
4. Carmeli Y., Troillet N., Karchner A.W., Samore M.H. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med. 159:1999;1127-1132.
5. CDC National Nosocomial Infections Surveillance System (1999). Antimicrobial Resistance Surveillance Report. http://www.cdc.gov/ncidod/hip/NNIS/ARSurv1198.htm (Updated February 24, 1999).
6. Edmond M.B., Wallace S.E., McClish D.K., Pfaller M.A., Jones R.N., Wenzel R.P. Nosocomial bloodstream infections in United States hospitals a three-year analysis . Clin Infect Dis. 29:1999;239-244.
7. Itokazu G.S., Quinn J.P., Bell-Dixon C., Kahan F.M., Weinstein R.A. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units evaluation of a national postmarketing surveillance program . Clin Infect Dis. 23:1996;779-784.
8. Jones R.N., Biedenbach D.J., Marshall S.A., Pfaller M.A., Doern G.V. Evaluation of the Vitek system to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime. Diagn Microbiol Infect Dis. 32:1998;1007-1110.
9. Jones, R. N., Pfaller, M. A., Doern, G. V., Erwin, M. E., Hollis, R. J., & the Cefepime Study Group. (1998). Antimicrobial activity and spectrum investigation of eight broad-spectrum β-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Diagn Microbiol Infect Dis 30, 215-228.
10. Kessler R.E., Fung-Tomc J. Susceptibility of bacterial isolates to β-lactam antibiotics from U.S. clinical trials over a 5-year period. Am J Med. 100:(suppl 6A):1996;13S-19S.
11. National Committee for Clinical Laboratory Standards (1997). Methods For Dilution Antimicrobial Tests For Bacteria That Grow Aerobically: Approved Standard M7-A4, 4th edition. Wayne, PA: NCCLS.
12. National Committee for Clinical Laboratory Standards (1999). Performance Standards For Antimicrobial Susceptibility Testing; 8th Informational Supplement M100-S9. Wayne, PA: NCCLS.
13. Pfaller, M. A., Jones, R. N., Doern, G. V., Kugler, K., & the SENTRY Participants Study Group. (1998) Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob Agents Chemother 42, 1762-1770.
14. Richards, M. J., Edwards, J. R., Culver, D. H., & Gaynes, R. P. (1999). Nosocomial infections in pediatric intensive care units in the United States. Pediatrics 103:e39. http://www.pediatrics.org/cgi/content/full/103/3/e39.
15. Richards M.J., Edwards J.R., Culver D.H., Gaynes R.P. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System Crit Care Med. 27:1999;887-892.
16. Schaberg D.R., Culver D.H., Gaynes R.P. Major trends in the microbiology of nosocomial infections. Am J Med. 91:(suppl 3B):1991;72S-75S.